Skip to content

A randomised cross-over trial to compare the effects of calcium citrate, dairy products and calcium-fortified fruit juice on serum calcium concentrations in normal postmenopausal women

In postmenopausal women what are the effects of calcium citrate, dairy products and calcium-fortified fruit juice on serum calcium concentrations?

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000342617
Enrollment
10
Registered
2014-03-31
Start date
2012-10-26
Completion date
2013-05-05
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Calcium supplements have been associated with increased cardiovascular risk, which might be related to their acute effects on serum calcium. This study aims to compare the effects on serum calcium of 0.5 g of calcium as citrate fasting, as citrate after a protein and fat rich meal, from unfortified dairy products or from calcium-fortified juice.

Interventions

A single dose of each of the following three treatments after fasting for at least 8 hours: 0.5 g of calcium as citrate (oral tablet) after a meal containing protein and fat, 0.5 g of calcium from unfortified dairy products (milk, yoghurt and cheese) or 0.5 g of calcium from a calcium-fortified fruit juice. Each dose will be separated by at least 7 days.

Sponsors

University of Auckland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
Yes

Inclusion criteria

Female, postmenopausal 5 years or more (menopause defined as at least 12 months since last period in a woman aged > 45 yrs with intact uterus, or serum oestradiol < 100 pmol/l with FSH > 50 IU/l in younger or hysterectomised woman).

Exclusion criteria

Renal impairment (serum creatinine >0.15 mmol/L), chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness (including malignancy), active major gastrointestinal disease, metabolic bone diseases, or serum ALP >normal, primary hyperparathyroidism, current or expected use of oral glucocorticoid drugs during the trial period, current or past use of bisphosphonate therapy in the preceding 2 years, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026